MARKETS
Earnings

Knight Therapeutics Raises FY2026 Sales Guidance from C$510.000M-C$525.000M to C$540.000M-C$560.000M vs C$519.863M Est

Aug 6, 2026 · 07:36 AM ET· updated 1h ago

Knight Therapeutics (TSX:GUD) raises FY2026 sales outlook from C$510.000 million-C$525.000 million to C$540.000 million-C$560.000 million vs C$519.863 million estimate.

Share
Why It Matters

Knight Therapeutics thinks it will make more money next year than it said before—about C$40 million extra. When a company raises its money prediction, it usually means their business is doing better than expected, which is something to watch.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.